Kim Coghill

Rigel's Stock Leaps On R112 Phase II Allergic Rhinitis Data

Aug. 3, 2004

OSI, Genentech Submit NDA For Tarceva As Therapy For NSCLC

Aug. 3, 2004

OSI Pharmaceuticals Inc. and partner Genentech Inc. completed the submission of a new drug application for Tarceva, a drug for the treatment of patients with advanced non-small-cell lung cancer who have failed chemotherapy. (BioWorld Today)

OSI, Genentech Submit NDA For Tarceva As Therapy For NSCLC

Aug. 3, 2004

By Kim Coghill

OSI Pharmaceuticals Inc. and partner Genentech Inc. completed the submission of a new drug application for Tarceva, a drug for the treatment of patients with advanced non-small-cell lung cancer who have failed chemotherapy. (BioWorld Today)